Jodi Lyn Layton
Papers
1
Total Citations
4
H-Index
1
About
Dr. Jodi Lyn Layton is a clinical researcher whose work centers on advancing therapeutic strategies for high-risk prostate cancer, with a particular focus on neoadjuvant chemotherapy approaches. Her most cited study, a Phase I/II clinical trial published in 2012, investigated the impact of neoadjuvant weekly ixabepilone in patients with high-risk prostate cancer. This work addressed critical gaps in treatment, exploring whether neoadjuvant chemotherapy could achieve tumor downstaging and target micrometastatic disease—a concept that had shown limited success with prior agents like docetaxel. Dr. Layton’s trial demonstrated promising activity for ixabepilone, offering a potential alternative to improve outcomes in a patient population with significant unmet needs. Although her citation count is modest, her contributions are notable for tackling a challenging clinical scenario and providing foundational data that informs ongoing research into perioperative therapies. Dr. Layton’s work underscores the importance of rigorous clinical investigation in refining cancer treatment paradigms, making her a dedicated contributor to the field of urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1